In today’s recent session, 0.64 million shares of the Acrivon Therapeutics Inc (NASDAQ:ACRV) have been traded, and its beta is 1.94. Most recently the company’s share price was $1.86, and it changed around $0.36 or 24.00% from the last close, which brings the market valuation of the company to $58.32M. ACRV at last check was trading at a discount to its 52-week high of $11.51, offering almost -518.82% off that amount. The share price’s 52-week low was $1.30, which indicates that the recent value has risen by an impressive 30.11% since then. We note from Acrivon Therapeutics Inc’s average daily trading volume that its 10-day average is 0.26 million shares, with the 3-month average coming to 130.88K.
Acrivon Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended ACRV as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Acrivon Therapeutics Inc is expected to report earnings per share of -0.65 for the current quarter.
Acrivon Therapeutics Inc (NASDAQ:ACRV) trade information
Instantly ACRV has been showing a green trend so far today with a performance of 24.00% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 2.0500 on recent trading dayincreased the stock’s daily price by 9.27%. The company’s shares are currently down -69.10% year-to-date, but still up 36.76% over the last five days. On the other hand, Acrivon Therapeutics Inc (NASDAQ:ACRV) is -66.18% down in the 30-day period. We can see from the shorts that 0.89 million shares have been sold at a short interest cover period of 5.43 day(s).
The consensus price target as assigned by Wall Street analysts is $27, which translates to bulls needing to increase their stock price by 93.11% from its current value. Analyst projections state that ACRV is forecast to be at a low of $27 and a high of $27.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -74.96%. Acrivon Therapeutics Inc earnings are expected to increase by -12.13% in 2025, but the outlook is negative -1.43% per year for the next five years.
ACRV Dividends
Acrivon Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Mar-26.
Acrivon Therapeutics Inc (NASDAQ:ACRV)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 21.95% of Acrivon Therapeutics Inc shares, and 74.42% of them are in the hands of institutional investors. The stock currently has a share float of 95.35%. Acrivon Therapeutics Inc stock is held by 91.0 institutions, with RA CAPITAL MANAGEMENT, L.P. being the largest institutional investor. By 2024-06-30, it held 23.083% of the shares, which is about 8.34 million shares worth $48.37 million.
PERCEPTIVE ADVISORS LLC, with 14.8366% or 5.36 million shares worth $31.09 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 407.49 shares worth $0.73 million, making up 1.30% of all outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held roughly 281.1 shares worth around $0.5 million, which represents about 0.90% of the total shares outstanding.
